Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides 5 methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
1 . A crystal form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) having structure
or a hydrate thereof,
wherein the crystal form is selected from form K′, form M, form H B , and form Q.
2 . The crystal form of claim 1 , wherein the form is form K′ of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 5.3, 12.3, and 22.5, ±0.2 °2θ.
3 . The crystal form of claim 1 , wherein the form is form K′ of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 5.3, 10.6, 12.3, 21.2, 22.5, and 23.0, ±0.2 °2θ.
4 . A method of preparing a crystal form K′ of compound I of claim 2 , comprising evaporating a solution of compound I in about 1:1 (v/v) n-butanol/dichloromethane, to crystallize compound I as crystal form K′.
5 . The crystal form of claim 1 , wherein the form is form M of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 11.1, 18.5, and 19.1, ±0.2 °2θ.
6 . The crystal form of claim 1 , wherein the form is form M of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 11.1, 12.1, 18.5, 19.1, 20.1, and 21.4, ±0.2 °2θ.
7 . A method of preparing a crystal form M of compound I of claim 5 , comprising slurrying compound I crystal form B in acetone at room temperature for at least 24 hours, to provide crystal form M.
8 . The crystal form of claim 1 , wherein the form is form H B of the hydrate of compound I, characterized by an X ray diffraction pattern having three or more peaks at 2θ values selected from 6.6, 12.2, and 15.8, ±0.2 °2θ.
9 . The crystal form of claim 1 , wherein the form is form H B of the hydrate of compound I, characterized by an X ray diffraction pattern having three or more peaks at 2θ values selected from 6.6, 12.2, 14.6, 15.8, 16.1, 18.5, 20.9, and 24.7, ±0.2 °2θ.
10 . A method of preparing crystal form H B of the hydrate of compound I of claim 8 , comprising slurrying compound I crystal form B in an about 1:1 mixture of acetone and water at room temperature for at least 5 days, at least 6 days, or at least 7 days, to provide crystal form H B .
11 . The crystal form of claim 1 , wherein the form is form Q of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 11.2, 12.2, and 19.1, ±0.2 °2θ.
12 . The crystal form of claim 1 , wherein the form is form Q of compound I, characterized by an X ray diffraction pattern having three or more peaks at 20 values selected from 11.2, 12.2, 18.5, 19.1, 20.1, 22.0, 22.5, 23.3, and 26.5, ±0.2 °2θ.
13 . A method of preparing crystal form Q of compound I of claim 11 , comprising slurrying compound I crystal form B in about 1:1 (v/v) n-butanol/dichloromethane, to obtain crystal form Q.
14 . A pharmaceutical formulation, comprising one or more crystal forms of claim 1 and a pharmaceutically acceptable excipient.
15 . An aqueous formulation comprising
one or more crystal forms of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) having structure
or a hydrate thereof,
wherein the crystal form is selected from form K′, form M, form H B , and form Q, in an amount of about 0.5% w/v to about 3.5% w/v, present as a suspension in the formulation;
a non-ionic surfactant;
a suspending agent;
a tonicity agent;
a buffer;
a salt; and
optionally, a preservative.
16 . The aqueous formulation of claim 15 , wherein the non-ionic surfactant is selected from the group consisting of a polysorbate surfactant, a block copolymer of ethylene oxide/propylene oxide surfactant, poloxamer, tyloxapol, and combinations thereof; or
wherein the suspending agent is carbomer, present in the formulation in an amount of at least about 0.05% w/v, at least about 0.1% w/v, or at least about 0.2% w/v, and no greater than about 1.0% w/v, no greater than about 0.6% w/v, or no greater than about 0.5% w/v; or
wherein the suspending agent is hydroxypropyl methyl cellulose present in the formulation in an amount of at least about 0.05% w/v, at least about 0.1% w/v, or at least about 0.25% w/v, and less than about 1.8% w/v, less than about 1.0% w/v, less than about 0.8% w/v, or less than about 0.6% w/v; or
wherein the suspending agent is a polyethylene glycol (PEG) having molecular weight of from about 200 to about 20,000 Da.
17 . The aqueous formulation of claim 15 , wherein the tonicity agent is selected from the group consisting of polyols, or wherein the buffer is selected from the group consisting of acetate, ascorbate, borate, hydrogen carbonate, carbonate, citrate, edetate (EDTA) gluconate, lactate, phosphate, propionate and TRIS (tromethamine).
18 . The aqueous formulation of claim 15 , wherein the pH of the formulation is about 5.5 to about 8.0.
19 . A method of treating or reducing ocular surface pain in a subject in need thereof, comprising ocularly administering an effective amount of a crystal form of claim 1 to the subject.
20 . A method of treating or reducing ocular surface pain in a subject in need thereof, comprising ocularly administering an effective amount of an aqueous formulation of claim 15 .